Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2018, Article ID 6703963, 14 pages
https://doi.org/10.1155/2018/6703963
Research Article

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States

1RTI Health Solutions, 2nd Floor, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester M20 2LS, UK
2Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
3Eli Lilly GmbH, Koelblgasse 8, 1030 Vienna, Austria
4RTI Health Solutions, 1440 Main Street, Suite 310, Waltham, MA 02451, USA
5Eli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK

Correspondence should be addressed to Lisa M. Hess; moc.yllil@m_asil_sseh

Received 7 September 2017; Accepted 29 November 2017; Published 26 March 2018

Academic Editor: Valerae O. Lewis

Copyright © 2018 Santiago Zuluaga-Sanchez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Santiago Zuluaga-Sanchez, Lisa M. Hess, Sorrel E. Wolowacz, et al., “Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States,” Sarcoma, vol. 2018, Article ID 6703963, 14 pages, 2018. https://doi.org/10.1155/2018/6703963.